BGI Genomics Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
3,580
- Stock Symbol
-
300676
- Investments
-
40
- Share Price
-
$5.16
- (As of Thursday Closing)
BGI Genomics General Information
Description
BGI Genomics Co Ltd is a China-based company principally engaged in the provision of genomic class diagnosis and research services through the application of biotechnology. It offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company mainly provides services for domestic and overseas academic institutions hospitals, medical institutions and others.
Contact Information
Website
www.bgi.comCorporate Office
- BGI Spacetime Center, No. 9 Yunhua Road
- Meisha Street, Yantian District
- Shenzhen, Guangdong 518083
- China
Corporate Office
- BGI Spacetime Center, No. 9 Yunhua Road
- Meisha Street, Yantian District
- Shenzhen, Guangdong 518083
- China
BGI Genomics Stock Performance
As of 19-Nov-2026, BGI Genomics’s stock price is $5.16. Its current market cap is $2.16B with 418M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.16 | $5.22 | $4.81 - $9.32 | $2.16B | 418M | 10.8M | -$0.19 |
BGI Genomics Financials Summary
As of 30-Sep-2026, BGI Genomics has a trailing 12-month revenue of $540M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,485,968 | 2,297,480 | 1,878,116 | 2,186,348 |
| Revenue | 540,272 | 515,258 | 538,909 | 614,800 |
| EBITDA | (76,288) | (18,876) | (66,377) | 69,526 |
| Net Income | (79,070) | (85,750) | (125,803) | 13,131 |
| Total Assets | 1,656,355 | 1,679,258 | 1,718,098 | 1,920,409 |
| Total Debt | 107,517 | 91,528 | 64,752 | 154,672 |
BGI Genomics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
BGI Genomics Comparisons
Industry
Financing
Details
BGI Genomics Competitors (23)
One of BGI Genomics’s 23 competitors is Novogene, a Formerly PE-Backed company based in Beijing, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novogene | Formerly PE-Backed | Beijing, China | ||||
| Dante Labs | Private Equity-Backed | New York, NY | ||||
| Genuity Science | Formerly VC-backed | Dublin, Ireland | ||||
| Gene By Gene | Formerly VC-backed | Houston, TX | ||||
| Agendia | Venture Capital-Backed | Irvine, CA |
BGI Genomics Patents
BGI Genomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026227447-A1 | Method for enrichment of enzymatic digestion product, library construction method, and use thereof | Pending | 30-Apr-2025 | ||
| WO-2026227325-A1 | Primer set and kit for detecting smn1 and smn2 gene mutations and use thereof | Pending | 29-Apr-2025 | ||
| WO-2026227340-A1 | Primer set for detecting number of cgg repeats and agg interruptions in fmr1 gene, and use thereof | Pending | 29-Apr-2025 | ||
| WO-2026227347-A1 | Primer set, kit and method for detecting cyp21a2 gene mutation | Pending | 29-Apr-2025 | ||
| WO-2026152464-A1 | Multi-omics detection method for plasma cfdna and use thereof | Pending | 20-Jan-2025 |
BGI Genomics Signals
BGI Genomics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
BGI Genomics Investments & Acquisitions (40)
BGI Genomics’s most recent deal was a Joint Venture with Xingtai Gene. The deal was made on 16-Dec-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Xingtai Gene | 16-Dec-2025 | Joint Venture | Laboratory Services (Healthcare) | ||
| Geneplus Technology | 31-Jul-2025 | Secondary Transaction - Private | Laboratory Services (Healthcare) | ||
| HyperSilicon | 26-Mar-2024 | Later Stage VC | General Purpose Semiconductors | ||
| Genolmmune Therapeutics | 28-Dec-2022 | Later Stage VC | Drug Discovery | ||
| Bamble AI Training | 14-Dec-2022 | Accelerator/Incubator | Business/Productivity Software |
BGI Genomics ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
20.57 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 67
Rank
Percentile
BGI Genomics Exits (6)
BGI Genomics’s most recent exit was on 30-Apr-2019 from Congenica. The exit was categorized as with 9 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Congenica | 30-Apr-2019 | Completed |
|
||
| Baidao Medical | 10-Dec-2018 | Completed |
|
||
| He's Eye Hospital | 07-Dec-2017 | Completed |
|
||
| He's Eye Hospital | 07-Dec-2017 | Completed |
|
||
| Gendi Healthcare | 23-Jun-2016 | Seed Round | Completed |
BGI Genomics Affiliates
Subsidiaries (7)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Huada GreenPine Angel Fund | Shenzhen, China | 2021 | |
| Hemu Gene Biotechnology | Shenzhen, China | 2018 | |
| Genolmmune Therapeutics | Wuhan, China | 2017 | |
| MGI Tech | Shenzhen, China | 2016 | |
| Miracle Light Venture | Shenzhen, China | 2016 |
BGI Genomics FAQs
-
When was BGI Genomics founded?
BGI Genomics was founded in 1999.
-
Where is BGI Genomics headquartered?
BGI Genomics is headquartered in Shenzhen, China.
-
What is the size of BGI Genomics?
BGI Genomics has 3,580 total employees.
-
What industry is BGI Genomics in?
BGI Genomics’s primary industry is Laboratory Services (Healthcare).
-
Is BGI Genomics a private or public company?
BGI Genomics is a Public company.
-
What is BGI Genomics’s stock symbol?
The ticker symbol for BGI Genomics is 300676.
-
What is the current stock price of BGI Genomics?
As of 19-Nov-2026 the stock price of BGI Genomics is $5.16.
-
What is the current market cap of BGI Genomics?
The current market capitalization of BGI Genomics is $2.16B.
-
What is BGI Genomics’s current revenue?
The trailing twelve month revenue for BGI Genomics is $540M.
-
Who are BGI Genomics’s competitors?
Novogene, Dante Labs, Genuity Science, Gene By Gene, and Agendia are some of the 23 competitors of BGI Genomics.
-
What is BGI Genomics’s annual earnings per share (EPS)?
BGI Genomics’s EPS for 12 months was -$0.19.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process